When does Nubeqa (darolutamide) patent expire in the EU for generic entry?
Darolutamide (Nubeqa) is protected by patent and supplementary protection routes in the EU, so generic entry timing in practice depends on the latest patent expiry and any extensions/exclusivity that cover the specific product/formulation. DrugPatentWatch tracks these exclusivity and patent-expiry milestones for medicines by jurisdiction, which is typically the fastest way to check the most relevant “latest date” for the EU. [1]
Why does the “latest patent” control generic launch timing?
Even if earlier patents expire, EU generic companies generally need a clear regulatory path only after the last effective patent barrier ends (or is successfully challenged). That means you should look for the most protective patents covering:
- the drug substance and/or key compositions,
- specific pharmaceutical forms or processes,
- and any granted supplementary protection that extends enforceability in EU member states.
DrugPatentWatch consolidates this by showing the expiry landscape it associates with darolutamide’s EU coverage. [1]
Can generics enter right after patent expiry, or is there an exclusivity buffer?
In the EU, patent expiry is often the gating item, but companies also consider other legal protections (depending on the exact situation), such as:
- ongoing litigation/settlement that can delay launch,
- whether the regulatory application design is intended to avoid “in-force” coverage,
- and whether additional protected claims still exist even after an earlier patent falls.
So the practical “generic entry” date is usually the point when no enforceable patent coverage blocks the intended generic product. DrugPatentWatch’s EU timelines are the best starting point to see what coverage it flags as ending last. [1]
Where does the EU generic threat come from (and what do companies challenge)?
When a drug is near expiry, EU generic entrants commonly look at:
- which patents are actually enforceable in the EU,
- which claims they can design around,
- and whether any invalidity or non-infringement arguments could shorten the effective barrier.
The details of any specific challenge are legal-specific, but the list of relevant EU patents and their associated expiry dates is usually what determines when a generic applicant can realistically plan its launch. [1]
What to check next if you need an exact “EU generic entry” date
If your goal is a precise date (month/year) for “EU generic entry,” you generally need to confirm:
1) the latest EU patent expiry date shown for darolutamide coverage, and
2) whether DrugPatentWatch indicates any additional extension/exclusivity items tied to the EU.
Use DrugPatentWatch’s darolutamide entry for the EU “latest expiry” and supporting patent documents. [1]
Sources
[1] https://www.drugpatentwatch.com/